Tian Tian

Prof. Dr. Tian Tian

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2019 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
HZHuixin Zhang
Huixin Zhang
JWJin Wu
Jin Wu
JWJiahuan Wu
Jiahuan Wu
QFQi Fan
Qi Fan
JZJingchao Zhou
Jingchao Zhou
JGJun Gao
Jun Gao
Accumulating evidence shows that microRNA-210 (miR-210) holds great promise to improve angiogenesis for brain tissue repair after cerebral ischemia. However, safe and efficient delivery of miR-210 via intravenous administration is still a challenge. In the past decade, exosomes have emerged as a novel endogenous delivery system. Here, c(RGDyK) peptide is conjugated to exosomes, and they are loaded with cholesterol-modified miR-210 (RGD-exo:miR-210). In a transient middle cerebral artery occlusion (MCAO) mouse model, the RGD-exo:miR-210 targets the lesion region of the ischemic brain after intravenous administration, resulting in an increase in miR-210 at the site. Furthermore, RGD-exo:miR-210 are administered once every other day for 14 days, and the expressions of integrin β3, vascular endothelial growth factor (VEGF) and CD34 are significantly upregulated. The animal survival rate is also enhanced. These results suggest a strategy for the targeted delivery of miR-210 to ischemic brain and provide an angiogenic agent for the treatment of ischemic stroke.

1 January 2021 in Theranostics
Verified
Journal Article
Open access
TTTian Tian
Tian Tian
LCLei Cao
Lei Cao
CHChuan He
Chuan He
QYQing Ye
Qing Ye
RLRuyu Liang
Ruyu Liang
JGJun Gao
Jun Gao
Ischemic stroke remains a major cause of death, and anti-inflammatory strategies hold great promise for preventing major brain injury during reperfusion. In the past decade, stem cell-derived extracellular vesicles (EVs) have emerged as novel therapeutic effectors in immune modulation. However, the intravenous delivery of EVs into the ischemic brain remains a challenge due to poor targeting of unmodified EVs, and the costs of large-scale production of stem cell-derived EVs hinder their clinical application.

31 January 2022 in ACS Nano
Verified
Journal Article
Closed access
TTTian Tian
Tian Tian
RLRuyu Liang
Ruyu Liang
GEGulsah Erel-Akbaba
Gulsah Erel-Akbaba
LSLorenzo Saad
Lorenzo Saad
POPierre J. Obeid
Pierre J. Obeid
BTBakhos A. Tannous
Bakhos A. Tannous

1 October 2020 in Hypertension
Verified
Journal Article
Closed access
PDF file
JWJie Wang
Jie Wang
LHLi Hu
Li Hu
HHHuijie Huang
Huijie Huang
YYYanfang Yu
Yanfang Yu
JWJingshen Wang
Jingshen Wang
FCFeng Chen
Feng Chen
In recent years, mesenchymal stem cells (MSCs)–derived extracellular vesicles (EVs) are emerging as a potential therapeutic agent for pulmonary hypertension (PH). However, the full realization of MSCs-derived EVs therapy has been hampered by the absence of standardization in MSCs culture and the challenges of industrial scale-up. The study was to exploit an alternative replacement for MSCs using currently commercialized stem cell lines for effective targeted PH therapy. ReNcell VM—a human neural stem cell line—has been utilized here as a reliable and easily adoptable source of EVs. We first demonstrated that ReNcell-derived EVs (ReNcell-EVs) pretreatment effectively prevented Su/Hx (SU5416/hypoxia)-induced PH in mice. Then for targeted therapy, we conjugated ReNcell-EVs with CAR (CARSKNKDC) peptide (CAR-EVs)—a peptide identified to specifically target hypertensive pulmonary arteries, by bio-orthogonal chemistry. Intravenous administration of CAR-EVs selectively targeted hypertensive pulmonary artery lesions especially pulmonary artery smooth muscle cells. Moreover, compared with unmodified ReNcell-EVs, CAR-EVs treatment significantly improved therapeutic effect in reversing Su/Hx-induced PH in mice. Mechanistically, ReNcell-EVs inhibited hypoxia-induced proliferation, migration, and phenotype switch of pulmonary artery smooth muscle cells, at least in part, via the delivery of its endogenous highly expressed miRNAs, let-7b-5p, miR-92b-3p, and miR-100-5p. In addition, we also found that ReNcell-EVs inhibited hypoxia-induced cell apoptosis and endothelial-mesenchymal transition in human microvascular endothelial cells. Taken together, our results provide an alternative to MSCs-derived EVs–based PH therapy via using ReNcell as a reliable source of EVs. Particularly, our CAR-conjugated EVs may serve as a novel drug carrier that enhances the specificity and efficiency of drug delivery for effective PH-targeted therapy.

5 August 2022 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
TTTian Tian
Tian Tian
SQShuya Qiao
Shuya Qiao
BTBakhos A. Tannous
Bakhos A. Tannous

19 May 2024 in Journal of Controlled Release
Verified
Journal Article
Closed access
RLRuyu Liang
Ruyu Liang
HLHongyu Lu
Hongyu Lu
HZHaifeng Zhu
Haifeng Zhu
GLGaofeng Liang
Gaofeng Liang
JZJunxi Zhang
Junxi Zhang
TTTian Tian
Tian Tian